Integrated traditional Chinese and conventional medicine in the treatment of anemia due to lower-risk myelodysplastic syndrome: study protocol for a randomized placebo-controlled trial

Qin Zheng 1, Haitao Xu 1, Luxi Song 2, Zeying Yan 4, Manqin Sun 2, Xia Peng 2, Yiling Jiang 1, Ling Shi 1, Aiping Zhang 1, Zhihao Wu 1, Jiahui Lu 2* and Meihong Luo 1*

Abstract

Background: Erythropoiesis and iron homeostasis are closely related; anemia due to lower-risk myelodysplastic syndromes (MDS) remains difficult to treat. In the last decade, we have been committed to improving the regulation of iron metabolism using traditional Chinese medicine (TCM). Previous studies have found that the TCM Yi Gong San (YGS) can reduce the expression of transferrin by inhibiting hepcidin overexpression caused by inflammation, promote the outward transfer of intracellular iron, and improve the symptoms of anemia. Here, our study aimed to compare the efficacy of a conventional drug with YGS with that of conventional medicine with placebo to provide a scientific basis for making clinical decisions.

Methods: A prospective, multicenter, double-blinded, randomized controlled clinical trial will be conducted to evaluate the therapeutic efficacy of conventional medicine combined with YGS with that of conventional medicine alone in the treatment of MDS. A total of 60 patients would be enrolled in this study, with each treatment group (conventional medicine + YGS and conventional medicine + placebo) comprising 30 patients. Oral medication would be administered twice daily for 3 months. All patients would be followed up throughout the 3-month period. The primary outcome was measured by assessing blood hemoglobin level. The secondary outcome was measured by assessing TCM symptom score, iron metabolism, hepcidin levels, and inflammatory factors.

Discussion: This trial would aim to demonstrate the effectiveness and feasibility of YGS in the treatment of lower-risk MDS anemia, as well as its impact on inflammatory factors and iron metabolism in patients with lower-risk MDS.
Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms characterized as a clonal disorder of the hematopoietic stem/progenitor cells leading to a host of hematological malignancies. MDS can be manifested as one or more morbid hematopoiesis of the bone marrow hematopoietic cells, ineffective hematopoiesis, and high-risk acute myeloid leukemia transformation [1]. Anemia is the most common clinical manifestation in patients with MDS. Approximately 60%–80% of patients have symptoms of anemia, and nearly 50% of MDS patients have severe anemia with an increased risk for heart and lung failure. Patients with International Prognostic Scoring System-Revised score of ≤3.5 has been categorized as lower-risk MDS subpopulation according to the 2012 International Working Group criteria. According to the European MDS statistics, lower-risk MDS accounts for approximately 70% of the entire MDS population, and most lower-risk MDS patients have symptomatic anemia; therefore, improving anemia and alleviating the symptoms of anemia are the main treatment goals for patients with lower-risk MDS [2].

The clinical treatment of lower-risk MDS anemia has always been a challenging task, despite the development of various treatment methods in Western medicine, including erythropoietin, immunosuppressants (cyclosporine A), immunomodulators (lenalidomide amine and thalidomide), and those undergoing clinical trials. A previous study reported that in patients with MDS anemia treated with the aforementioned drugs, 80–90% still require blood transfusion, and blood transfusion dependence (1 U red blood cell transfusion at least every 8 weeks within 4 months) is negatively related to patient survival [3].

Lower-risk MDS anemia, also known as ineffective hematopoiesis, is primarily caused by the excessive proliferation of red blood cell precursors, which fail to mature and impair the ability of red blood cells to carry oxygen in the blood. Additionally, erythropoiesis and iron homeostasis are closely related. Abnormal iron metabolism is an independent risk factor affecting the prognosis of patients with lower-risk MDS [2], and hepcidin plays a key role in iron homeostasis. MDS has a complex iron regulation mechanism: anemia, hypoxia, inflammation, and iron overload, which have opposite effects on hepcidin production. Compared with healthy individuals, patients with MDS deprived of blood transfusion have significantly increased serum ferritin (SF) and hepcidin levels, but have decreased hepcidin/SF ratio [4, 5]. In patients with lower-risk MDS undergoing blood transfusion, the hepcidin levels initially increase; however, as the amount of transfused blood increases, the hepcidin levels gradually decrease, eventually causing iron overload [6]. Iron overload would further aggravate the underlying hematopoiesis deficiency in those with MDS, making blood transfusion ineffective [2].

In the last decade, we have been committed to improving the mechanism of iron metabolism using traditional Chinese medicine (TCM). According to the TCM theory, spleen deficiency is an important triggering factor of MDS, and the approach called “tonifying the spleen” in TCM clinical practice is a crucial step of MDS treatment. The spleen is responsible for maintaining the normal distribution of iron in the body. The implementation of this function depends on the transportation of spleen Qi. Therefore, the deficiency of spleen Qi and the diminished function of spleen would cause an iron distribution disorder. Yi Gong San (YGS) is a representative TCM prescription for promoting the movement of spleen Qi. Previous studies have found that YGS used in TCM has no effect on iron metabolism in normal mice. However, it can reduce the expression of transferrin by inhibiting hepcidin overexpression caused by inflammation, promoting the outward transfer of intracellular iron and thus improving anemia [7–9]. Reports from many clinical trials have shown that YGS can improve inflammation-induced anemia (anemia due to chronic diseases) [10]. In fact, prior to blood transfusion, lower-risk MDS have the same pathological process of iron metabolism with anemia due to chronic diseases. However, it is not clear whether YGS is a suitable therapeutic candidate for anemia in patients with lower-risk MDS. Thus, this study aimed to compare the efficacy of conventional drug with YGS with that of conventional drug alone, as a basis for making clinical decisions.

Methods
Objective and design
This multicenter, pragmatic, randomized, and controlled trial is conducted to evaluate the effectiveness of integrating YGS into the conventional treatment for anemia in patients with lower-risk MDS. A total of 60 patients would be recruited and randomly assigned to one of the two treatment groups. During the treatment period, patients in both arms would be followed up for 3 months.
The primary outcome (hemoglobin) and secondary outcome measures (TCM symptom score, iron metabolism, hepcidin levels, and inflammatory factors) would be assessed at different points within the trial period.

The study has been approved by the research ethics committee of the Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine (#201809-01). This trial adhered to the Declaration of Helsinki and has been registered at the Chinese Clinical Trials Registry (ChiCTR1900026774) on October 21, 2019. The trial results would be reported according to the Standard Protocol Items: Recommendations for Interventional Trials statement and the latest version of the Consolidated Standards of Reporting Trials statement.

**Study setting and participants**

All adult patients with lower-risk MDS admitted at the respiratory departments in three tertiary care hospitals would be screened and enrolled. Eligible patients would be asked to provide an informed written consent and would be centrally randomized to either the integrated YGS and conventional medicine group or the conventional medicine group. For both groups, all medications would be administered orally for 3 months (12 weeks). Patient recruitment has begun in March 2020 and should be completed in December 2021.

The inclusion criteria are as follows:

- Patients aged ≥ 18 years and older
- Patients whose peripheral blood cell, bone marrow smear, gene, and chromosome profiles meet the criteria for lower-risk MDS according to the 2020 NCCN guidelines (V1)
- Patients with a hemoglobin level of < 110 g/L
- Patients whose symptoms meet the spleen Qi deficiency pattern of MDS according to the Standard Criteria for Syndrome Differentiation by TCM[11]

The exclusion criteria are as follows:

- Patients who are blood transfusion dependent
- Pregnant or lactating women, and women planning to become pregnant (must undergo urine pregnancy test, a standard test for women of childbearing age, before treatment)
- Patients with liver and kidney function insufficiency (whose blood aspartate aminotransferase, alanine aminotransferase, or creatinine concentrations exceed the normal value by more than 3 times the upper limit)
- Patients who recently participated in clinical trials of other drugs (within 2 weeks of TCM, within 7 half-lives of Western medicine)
- Patients with comorbidities that may cause anemia such as neoplastic diseases
- Patients who are unwilling to cooperate
- Patients who cannot complete the specified observation items after being selected

**Randomization and double-blind approach**

Participants who met the inclusion criteria and signed an informed consent form would be allocated to a group (Fig. 1). Based on a stratified block randomization design with a 1:1 ratio, two groups of patients would be assigned by the study center at the time of study. Allocation of patients is based on the random numbers (1 to 60) generated using an SPSS software version 25.0, and patient’s details are saved and kept in a sealed envelope by an independent clinical statistician based on the double-blind research method. In the study, the procedures of generating random numbers, evaluating the results of primary and secondary outcomes, and statistical analysis are independently performed by dedicated personnel who are blinded to outcome data. Upon completion of the study and data analysis, the efficacy and safety of YGS treatment shall be evaluated. During the clinical trial period, the treatment regimen of both study groups would be managed by their respective study center/hospital according to the approved treatment plan. If a patient develops a serious adverse reaction or life-threatening condition during the course of clinical trial, the clinician responsible for the patient must provide the best on-site medical care. Simultaneously, the clinician must immediately report the incidence to the inspector, upon which the letter containing patient’s treatment grouping information needs to be opened to break the blind, and the type of drug used is identified to ensure that the patient is provided with the appropriate emergency medical assistance. Once a blind is uncovered, the case would be regarded as a shedding case and would be excluded from the statistics, and any occurrence of adverse reactions would be recorded.

**Intervention treatment**

All patients would be treated with conventional medicine according to the MDS 2020 NCCN guidelines (V1) and TCM guidelines for the diagnosis and treatment of MDS (2019) [12]. For the conventional medicine and YGS treatment, patients would be given herbal interventions based on the spleen Qi deficiency pattern of MDS. YGS is an oral decoction containing five herbs: Ginseng Radix et Rhizoma (Ren-Shen), Glycyrrhizae Radix et Rhizoma (Gan-Cao), Citri Reticulatae Pericarpium (Chen-Pi), Atractylodis Macrocephalae Rhizoma (Bai-Zhu), and...
Poria Sclerotium (Fu-Ling). Granules containing these herbs are manufactured by Jiangyin Tianjiang Pharmaceutical Co., Ltd with strict compliance to Good Clinical Practice conditions in terms of the production process and packaging of mixed granules for TCM. Each YGS granule contains 20 g of each herbal raw material (Table 1).

For the conventional medicine group, patients would be administered placebos containing maltodextrin, lactose, and food coloring, according to the modern pharmaceutical technology and placebo specification for granules. The placebos appear identical to YGS granules in terms of packaging, weight, odor, and color. In all patients, the medications would be administered twice daily, after breakfast and dinner, and up to 3 months (12 weeks).

**Data collection**
Most patients in the outpatient clinic would be enrolled in the study. We would first obtain the patient's informed consent. Then, we will collect the patient's demographic data (sex, age, occupation, home address, diagnosis, and past history of illness) and help the patient fill out the TCM symptom score, Iron metabolism, hepcidin and inflammatory factors.

**Recruitment**
Anemia of lower-risk myelodysplastic syndrome

![Fig. 1 Flow chart of the study design](image-url)
liver and kidney function, iron metabolism-related indicators, hepcidin levels, and inflammatory factor-related markers. By randomly assigning them into either group, the patients would be administered with oral doses of conventional medicine with YGS or placebo for 3 months (12 weeks). At 1-, 2-, and 3-month intervals, the patients will be followed up in order to determine who among them would be suitable to fill up a new TCM symptom scale form to rate their symptoms, and a fresh peripheral blood samples would be collected (Table 2). Use case record form to collect patient clinical data and test data, and enter the information and data into electronic data capture.

### Efficacy assessment

#### Primary outcome

The primary outcome is the blood hemoglobin level; by comparing it to the baseline level prior to the initiation of treatment, an increase of 10 g/L is considered as an effective treatment outcome.

#### Secondary outcomes

The secondary outcomes measure the changes in TCM symptom scores, iron metabolism, hepcidin levels, and inflammatory factors. Spleen Qi deficiency syndrome is primarily characterized by poor appetite, fatigue, abdominal distension after meal or in the afternoon, and abnormal stool. The effectiveness of TCM is evaluated using the TCM syndrome score method (Table 3). According to the Standard Criteria for Syndrome Differentiation by TCM [11], a reduction in TCM syndrome score by ≥30% indicates that the clinical symptoms of spleen Qi deficiency either improved or disappeared and the treatment is considered clinically effective. The TCM syndrome score is calculated as follows: \( \frac{\text{[(scores before treatment} - \text{scores after treatment)} \div \text{scores before treatment}] \times 100\%}{\text{}} \). The indicators for iron metabolism are serum iron, total iron-binding capacity, SF, and soluble transferrin receptor. Inflammatory factors include interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α.

### Adverse event reporting

Details of the mild or severe adverse effects following TCM treatment would be recorded in the "case report form," which comprise the time of occurrence, clinical manifestations, number of treatment elapsed days, duration, outcome, and possible side effects of the drug. Patients with abnormal laboratory test results must be followed up until the test results return to normal or to the level prior to the administration of medications; the clinicians shall determine whether the abnormalities are related to the treatment drug. If a serious adverse reaction develops, the "serious adverse event form" should be filled out, and the incident would be reported to the sponsor, research ethics committee, the Safety Supervision Department of National Medical Products Administration, and the Health Administration Department within 24 h. The sponsor and research ethics committee in charge will conduct the quality control and patient compliance assessment in this trial.

### Sample size considerations

Based on the sample size estimation formula \( n_1 = n_2 = 2\times\left[\frac{\mu_\alpha + \mu_\beta}{\sigma/\delta}\right]^2 + \mu_\alpha^2 \), the main research outcome indicator is the change in hemoglobin (Hb) levels, which will be used to estimate the sample size; compared with the baseline results, the Hb level of the experimental group (conventional medicine + YGS) increased to 20 g/L, while the Hb level of the control group (conventional medicine + placebo) increased to 14 g/L (standard deviation: 7 g/L, \( n_1= \) group 1, \( n_2= \) group 2, \( \sigma=14, \delta=7, \) bilateral \( \alpha=0.05, \mu_\alpha=1.96, \) unilateral \( \beta=0.2, \mu_\beta=0.84)\); therefore, each group should comprise 22 patients; considering a 30% loss due to follow-up, each group should comprise 30 patients. Therefore, we intend to recruit 60 patients from March 2020 to December 2021.

### Statistical analyses

A descriptive statistical analysis of all the quantified variables in this study would be performed. The mean, median, and standard deviation will be calculated for quantitative variables, while the absolute and relative frequencies will be calculated for qualitative

---

### Table 1: Weight and composition of YGS and placebo granules

| Chinese name | Latin name                     | Granule weight (g) | Herbal raw material weight (g) |
|--------------|--------------------------------|--------------------|-------------------------------|
| Yi Gong San granules | 44.8                                        |
| Ren-Shen     | Ginseng Radix et Rhizoma        | 6.7                | 20                            |
| Bai-Zhu      | Atractylodis Macrocephalae Rhizoma | 14.7               | 20                            |
| Fu-Ling      | Poria Sclerotium                | 6.7                | 20                            |
| Chen-Pi      | Citri Reticulatae Pericarpium   | 8.2                | 20                            |
| Gan-Cao      | Glycyrrhizae Radix et Rhizoma   | 8.5                | 20                            |
| Placebo granules | 44.8                                          | 0                |                               |
| Study schedule for patients |
|-----------------------------|
| **Table 2** |

| Study period                  | Enrollment | Allocation | Post-allocation |
|-------------------------------|------------|------------|-----------------|
| Time point                    | <1 day     | 1 day      | 1, 2, and 3 months |

**Enrollment:**
- Eligibility screen: X
- Inform consent: X

**Allocation:**
- X

**Intervention:**
- Conventional medicine
- + YGS treatment
- Conventional medicine
- + Placebo treatment

**Efficacy and safety evaluation:**
- TCM symptom score: X
- Routine blood test: X
- Iron metabolism test: X
- Serum hepcidin test: X
- Inflammatory factors test: X
- Liver and renal function test: X
- Adverse events recording: X

**Others:**
- Randomized allocation: X
- Drug distribution: X
The SPSS software (version 25.0; IBM Inc., USA) would be used for data processing and analysis. Statistical analysis would be based on the intention-to-treat and per-protocol population principles. The missing data can be processed using the last observation carried forward method. To compare the changes in TCM symptom scores and hematological data of patients before and after taking intervention treatment, multiple comparisons would be performed. A repeat measurement data analysis of variance will be initially conducted followed by a separate effect analysis, including comparisons between groups at each time point, using a multivariate logistic regression model to analyze the correlation between iron metabolism, hepcidin levels, and IL-6, TNF-α, IL-1 expression changes, and curative effect. Additionally, a subgroup analysis can be performed according to the R-IPI, and covariance analysis can be performed considering the factors such as age and sex. A two-sided $P$ value of $<0.05$ is considered significant.

**Discussion**

The release of inflammatory factors plays an important role in the development of lower-risk MDS, including the upregulation of cytotoxic T cells [13]. Bone marrow fibroblasts and macrophages of patients with MDS continuously release IL-6, IL-1, TNFs, and other inflammatory factors to further aggravate the compromised hematopoiesis in the bone marrow and promote the apoptosis of bone marrow cells [14]. Patients with MDS often have a low immune function and increased co-infection risk especially those with leukopenia. Co-infection would further stimulate the release of inflammatory factors in the body, especially IL-6 and IL-1, that can induce liver hepcidin overexpression and inhibit iron absorption and release of stored iron [15], resulting in iron metabolism disorders that are similar to anemia induced by chronic diseases. C-reactive protein (CRP) levels indirectly reflect the expression of inflammatory factors. Previous studies have shown that serum CRP levels in patients with MDS are positively correlated with the hepcidin, especially the RAEB type [4]. Similar to SF, CRP has a significant effect on patient's survival, indirectly indicating that inflammatory factors can affect the survival of patients with MDS [2].

YGS is an oral concoction first reported in the Pediatric Medicine Card Straight Tactic, a famous

| Symptom                        | Score | Mild = 2 | Moderate = 4 | Severe = 6 |
|--------------------------------|-------|----------|--------------|------------|
| Reduced food intake            | No appetite, but maintain the original intake | Intake volume reduced by 1/3 compared before the onset of symptoms | Intake volume reduced by 2/3 compared before the onset of symptoms |
| Fatigue                        | Slightly tired and inactive but able to perform basic daily activities | Obvious sign of burnout, barely performing daily activities | Systemic weakness of the limbs, unable to perform daily activities |
| Bloating after meal            | Slight abdominal distension, which can disappear within half an hour; is not severe; and does not require medications | Slight abdominal distension, which can disappear within mild; is not severe; and does not require medications | Abdominal distension cannot be improved within 2 h, affecting life, or taking ineffective medicines |
| Abnormal stool                 | Soft stools or slightly watery stools, piles are not formed, frequency of bowel movements: 2–3 times/day | Watery stools, loose stools, frequency of bowel movements: 4–5 times/day or 1–2 times/day | Loose stools, more than 3 times/day |
| Reduced talkativeness/ responsiveness | Low energy, not interested to talk or respond | Mental fatigue, sleepy, not interested to engage in conversation | Extremely fatigued, idle |
| Absence of taste/thirst        | Occasional tasteless | Sometimes tasteless, reduced water intake | Persistent absence of taste, not thirsty all day long |
| Abdominal discomfort           | Occasional or faint abdominal pain | Abdominal pain often occurs, lasting no more than 2 h | Abdominal pain is more obvious, lasting more than 2 h, or persistent |
| Nausea and vomiting            | Occasionally nausea | Sometimes nausea, occasionally vomiting | Frequent nausea and vomiting |
| Excessive bowel gas            | Occasional | Often | Hyperactive |
| Yellowish complexion           | Yellowish complexion and reduced luster | Yellowish complexion and much reduced luster | Yellowish complexion and dull |
| Edema                          | Mild edema of the face or lower limbs | Edema of the face and limbs | Obvious body edema |
| Difficulty in Defecation       | Straining to defecate | Require great effort to defecate | Hard to defecate or severely constipated |

No symptom $= 0$
This study is currently in the process of recruiting patients. The protocol version number is 2.0, dated October 08, 2018. Recruitment of participants commenced on March 23, 2020, and is expected to end on December 31, 2021. At the time of manuscript submission, we have recruited 19 patients from three hospitals concurrently; therefore, this clinical trial is expected to be completed on time.

**Abbreviations**

MDS: Myelodysplastic syndromes; TCM: Traditional Chinese medicine; YGS: Yi Gong San; ChiCTR: Chinese clinical trials registry; SF: Serum ferritin; IL-1: Interleukin-1; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-α; CRP: C-reactive protein

**Acknowledgements**

We would like to acknowledge Professor Yu Chen from the Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and Professor Chun Kang Chang from the Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, for providing assistance in the application and preparation of the study. We would also like thank the Program for Key Subjects of Shanghai and the National Natural Science Foundation of China for funding this study.

**Authors’ contributions**

LJ and LM contributed to the design and development of the trial. LM is the principal investigator of the study. LJ drafted the manuscript; ZQ was responsible for the conception and design of the study, writing, and final approval of the manuscript. XH, YZ, XL, PX, and SM participated in the coordination of the trial and in the recruitment of study patients. JY, SL, ZA, and WZ were responsible for the data collection and analysis. All authors have reviewed the content and approved the final version of the manuscript.

**Funding**

This study is supported by the Program for Key Subjects of Scientific Research Project of Shanghai Municipal Health and Family Planning Commission (2018Y0094), Shanghai Municipal Health and Family Planning Commission Three-year Action Plan-Dominant Disease Cultivation Project (ZYI(2018-2020)-ZYBZ-32), the National Natural Science Foundation of China (81804021 and 81774271), and Shanghai Science and Technology Commission Three-year Action Plan-Dominant Disease Cultivation Project (1740051000). The funders had no role in the design of the study, collection, analysis, and interpretation of data and in writing or approving the manuscript.

**Availability of data and materials**

The datasets generated and/or analyzed during the current study are not publicly available, owing to the protection of privacy for patients, but they are available from the corresponding author upon reasonable request.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the research ethics committee of the Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine (identifier: 201809-01). All procedures performed in the studies involving human participants were carried out in accordance with the ethical standards of the institutional and/or national research ethics committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. A written informed consent would be obtained from each participant and would be provided to the patients for signature prior to the study enrollment. To encourage adherence to the treatment, all patients would receive the study drug and laboratory tests for free during the entire observational period. In order to protect the privacy of patients, the original materials are also stored in the hospital and cannot be accessed without the consent of the ethics committee. Data publication will also hide the patient’s name.

**Consent for publication**

Not applicable.
Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Hematology, Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine (Baoshan Hospital Affiliated to Shanghai University of Traditional Chinese Medicine), Shanghai 201999, China. 2Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China. 3Department of Hematology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 200233 Shanghai, China. 4Department of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 200020 Shanghai, China.

Received: 24 December 2020 Accepted: 19 September 2021

References
1. Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. The Lancet. 2014;383(9936):2239–52. https://doi.org/10.1016/S0140-6736(13)61901-7.
2. de Swart L, Reiniers C, Baguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, et al. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2018;103(1):69–79. https://doi.org/10.3324/haematol.2017.171884.
3. Shenoy N, Vallurupalli N, Rachmilewitz E, Verma A, Grunberg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124(6):873–81. https://doi.org/10.1182/blood-2014-03-563221.
4. Kaufman D, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6(8):e23109. https://doi.org/10.1371/journal.pone.0023109.
5. Cui R, Gale RP, Zhu G, Xu Z, Qin T, Zhang Y, et al. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. Leuk Res. 2014;38(5):545–50. https://doi.org/10.1016/j.leukres.2014.01.016.
6. Santini V, Grelli D, Sanna A, Martirelli N, Duca L, Camporinini N, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6(8):e23109. https://doi.org/10.1371/journal.pone.0023109.
7. Zheng Q, et al. Effect of Yi Gong San Decoction on Iron Homeostasis in a Mouse Model of Acute Inflammation. Evid Based Complement Alternat Med. 2016;2016:869480.
8. Zheng Q, et al. Impact of yigong powder on mice with iron metabolism disorder mediated by lipopolysaccharide. J Tradit Chin Med. 2015;56(20):1767–70.
9. Zheng, Q., et al. Therapeutic Effects of Yi Gong San Decoction on Anemia of Chronic Disease in Mouse. Lab Anim Comp Med, 2017,37(6): p1-7.
10. Xue C, et al. Yigong Powder combined with conventional western medicine in treating anemia of chronic disease (spleen qi deficiency syndrome): A randomized, double-blinded, placebo-controlled clinical trial. ShIJ.TCM. 2020;54(suppl1):81–5.
11. Chen YB. Standards for diagnosis and curative effect of Chi nese medical symptom: Nanjing University Publish ing House; 1994. p. 66–8.
12. Enculescu M, Metzendorf C, Sparla R, Hahnle M, Bode J, Muckenhauser MU, et al. Modelling Systemic Iron Regulation during Dietary Iron Overload and Acute Inflammation: Role of Hepcidin-Independent Mechanisms. PLoS Comput Biol. 2017;13(11):e1005322. https://doi.org/10.1371/journal.pcbi.1005322.
13. Hellström-Lindberg E, Tobiassson M, Greenberg P. Myelodysplastic syndromes: moving towards personalized management. Haematologica. 2020;105(7):1765–79. https://doi.org/10.3324/haemato12020.248955.
14. Braun T, Fenaux P. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? Best Pract Res Clin Haematol. 2013;26(4):327–36. https://doi.org/10.1016/j.beha.2013.03.003.
15. Reichert CO, da Cunha J, Levy D, Maselli LMF, Byddowski SP, Spada C. Hepcidin: Homeostasis and Diseases Related to Iron Metabolism. Acta Haematologica. 2017;137(4):220–36. https://doi.org/10.1159/000471838.
16. Kim SJ, Shin HJ, Lee BI, Kim DS, Lee JH, Jeong MY, et al. The antiinflammatory mechanism of Igongsan in mouse peritoneal macrophages via suppression of NF-kappaB/Caspase-1 activation. Phytother Res. 2014;28(5):736–44. https://doi.org/10.1002/ptr.3058.
17. Fozza C, Longinotti M. The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers. Leuk Res. 2013;37(2):201–3. https://doi.org/10.1016/j.leukres.2012.11.007.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.